CD274 and non-small cell lung carcinoma: In addition to its central role as a key element of current immunotherapy strategies, PD-L1 has emerged as a potential prognostic factor and biomarker to predict which patients are more likely to respond to immunotherapy in NSCLC [17,18,19,20,21,22,23,24,25,26].